NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary items found
Status Description Section
REDPaclitaxel  Malignant disease and immunosuppression, Taxanes, 08.01.05
REDPaclitaxel - Albumin Bound Formulation (nab-paclitaxel) Abraxane®; Pazenir®
(5 mg/ml powder for dispersion for infusion) 		Malignant disease and immunosuppression, Taxanes, 08.01.05
Searchiing the National BNF we found these items - Click button under Local to search local formulary or BNF to view on online BNF.
Local BNF Section
Paclitaxel Paclitaxel [Specialist Drug] Malignant Disease, Cytotoxic Responsive Malignancy, Antineoplastic Drugs Taxanes
Selecting a button in the local column will search the local formulary again for the word on the button. Where the button is in outline no local match at drug name level was found.
Links found
DSU Jan 2022 Paclitaxel formulations (conventional and nab-paclitaxel): caution required due to potential for medication error
DSU Jan 2022 Paclitaxel formulations (conventional and nab-paclitaxel): caution required due to potential for medication error
NICE TA108 Paclitaxel for the adjuvant treatment of early node-positive breast cancer
NICE TA1092: Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancer
NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cance
NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
NICE TA476 Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
NICE TA55 Guidance on the use of paclitaxel in the treatment of ovarian cancer
NICE TA600 Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
NICE TA639: Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer
NICE TA770 Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
NICE TA801 Pembrolizumab plus chemotherapy (paclitaxel or nab‑paclitaxel) for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer